Top

Clinical and Translational Oncology

Published in:

Open Access 01-11-2019 | Colorectal Cancer | Research Article

Clinical characteristics and prognosis of different primary tumor location in colorectal cancer: a population-based cohort study

Authors: C. Zheng, F. Jiang, H. Lin, S. Li

Published in: Clinical and Translational Oncology | Issue 11/2019

Abstract

Purpose

Emerging data have shown that patients with left-sided cancers have better survival than patients with right-sided cancers in terms of metastatic colorectal cancer. However, the available information and findings remain limited and contradictory in localized colorectal cancer. This study aimed to evaluate the clinical characteristics and prognosis of primary tumor location (PTL) in colorectal cancer.

Methods

Patients’ diagnoses were identified using the Surveillance, Epidemiology, and End Result database between 2006 and 2015. The analyses were further stipulated to patients with primary cancer site, histology, and stage information. The correlations between PTL and overall survival (OS) were assessed.

Results

Compared with left-sided tumors, right-sided tumors were more likely to develop into T3 cancers (50.0% vs. 44.8%), T4 cancers (15.8% vs. 12.3%), mucinous or mucin-producing adenocarcinoma (10.8% vs. 5.0%), and signet ring cell carcinoma (1.4% vs. 0.7%), P < 0.01, respectively. Patients with right-sided tumors showed inferior OS (56.1% vs. 60.2%), and the hazard ratio was 1.224 (95% CI, 1.208–1.241, P < 0.001) in all stages. Stage-specific Cox regression analysis revealed that patients with right-sided tumors also showed inferior OS in every stage (respectively, P < 0.05) than left-sided tumors.

Conclusions

This study demonstrated that the prognoses of patients with left-sided cancers were better than those of patients with right-sided cancers regardless of stage. PTL can be a prognosis factor in colorectal cancer. We encourage developing clinical and translational studies to elucidate the causative relationship between PTL and prognosis.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):359–86.CrossRef

Aran V, Victorino AP, Thuler LC, Ferreira CG. Colorectal cancer: epidemiology, disease mechanisms and interventions to reduce onset and mortality. Clin Colorectal Cancer. 2016;15(3):195–203.CrossRef

Lee GH, Malietzis G, Askari A, Bernardo D, Al-Hassi HO, Clark SK. Is right sided colon cancer different to left-sided colorectal cancer? A systematic review. Eur J Surg Oncol. 2015;41(3):300–8.CrossRef

Yahagi M, Okabayashi K, Hasegawa H, Tsuruta M, Kitagawa Y. The worse prognosis of right-sided compared with left-sided colon cancers: a systematic review and meta-analysis. J Gastrointest Surg. 2016;20(3):648–55.CrossRef

Loupakis F, Yang D, Yau L, Feng S, Cremolini C, Zhang W, et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst. 2015;107(9):djv203. https://doi.org/10.1093/jnci/djv203.CrossRef

Snyder M, Bottiglieri S, Almhanna K. Impact of primary tumor location on first-line bevacizumab or cetuximab in metastatic colorectal cancer. Rev Recent Clin Trials. 2018;13(2):139–49. https://doi.org/10.2174/1574887113666180328104109.CrossRefPubMed

Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V. The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials. Eur J Cancer. 2017;70:87–98.CrossRef

Petrelli F, Tomasello G, Borgonovo K, Ghidini M, Turati L, Dallera P, et al. Prognostic survival associated with left-sided vs right-sided colon cancer. A systematic review and meta-analysis. JAMA Oncol. 2017;3:211–9.CrossRef

Karim S, Brennan K, Nanji S, Berry SR, Booth CM. Association between prognosis and tumor laterality in early-stage colon cancer. JAMA Oncol. 2017;3(10):1386–92. https://doi.org/10.1001/jamaoncol.2017.1016.CrossRefPubMedPubMedCentral

10.

Warschkow Rene, Sulz Michael C, Marti Lukas, Tarantino Ignazio, Schmied Bruno M, Cerny Thomas, et al. Better survival in right-sided versus left-sided stage I–III colon cancer patients. BMC Cancer. 2016;16:554. https://doi.org/10.1186/s12885-016-2412-0.CrossRefPubMedPubMedCentral

11.

Surveillance, Epidemiology and End Results (SEER) Program (2014) Research Data (1973–2011), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, April 2014, https://seer.cancer.gov/. Accessed 12 May 2018.

12.

Wingo PA, Jamison PM, Hiatt RA, Weir HK, Gargiullo PM, Hutton M, et al. Building the infrastructure for nationwide cancer surveillance and control—a comparison between The National Program of Cancer Registries(NPCR) and The Surveillance, Epidemiology, and End Results (SEER) Program (United States). Cancer Causes Control. 2003;14(2):175–93.CrossRef

13.

Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, et al. International classification of diseases for oncology. 3rd ed. Geneva: World Health Organization; 2000.

14.

Benedix F, Kube R, Meyer F, Schmidt U, Gastinger I, Lippert H, Colon/rectum carcinomas (primary tumor) Study Group. Comparison of 17,641 patients with right and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum. 2010;53(1):57–64.CrossRef

15.

Missiaglia E, Jacobs B, D’Ario G, Di Narzo AF, Soneson C, Budinska E, et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol. 2014;25(10):1995–2001.CrossRef

16.

Riihimaki M, Hemminki A, Sundquist J, Hemminki K. Patterns of metastasis in colon and rectal cancer. Sci Rep. 2016;6:29765.CrossRef

17.

Weiss JM, Pfau PR, O’Connor ES, King J, LoConte N, Kennedy G, et al. Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results—medicare data. J Clin Oncol. 2011;29(33):4401–9.CrossRef

18.

Juo YY, Johnston FM, Zhang DY, Juo HH, Wang H, Pappou EP, et al. Prognostic value of CpG islandmethylator phenotype among colorectal cancer patients: a systematic review and meta-analysis. Ann Oncol. 2014;25(12):2314–27.CrossRef

19.

Cha Y, Kim KJ, Han SW, Rhee YY, Bae JM, Wen X, et al. Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer. Br J Cancer. 2016;115(2):164–71.CrossRef

20.

Lee Michael S, Menter David G, Kopetz Scott. Right versus left colon cancer biology: integrating the consensus molecular subtypes. J Natl Compr Canc Netw. 2017;15(3):411–9.CrossRef

21.

Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350–6.CrossRef

22.

Sears CL, Garrett WS. Microbes, microbiota, and colon cancer. Cell Host Microbe. 2014;15(3):317–28.CrossRef

23.

Johnson CH, Dejea CM, Edler D, Hoang LT, Santidrian AF, Felding BHI, et al. Metabolism links bacterial biofilms and colon carcinogenesis. Cell Metab. 2015;21(6):891–7.CrossRef

24.

Hugen N, Nagtegaal ID. Distinct metastatic patterns in colorectal cancer patients based on primary tumour location. Eur J Cancer. 2017;75:3–4. https://doi.org/10.1016/j.ejca.2017.01.003.CrossRefPubMed

25.

Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F, et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol. 2017;3(2):194–201. https://doi.org/10.1001/jamaoncol.2016.3797.CrossRef

26.

Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40.CrossRef

27.

van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12:575–82.CrossRef

28.

Roh MS, Colangelo LH, O’Connell MJ, Yothers G, Deutsch M, Allegra CJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol. 2009;27:5124–30.CrossRef

29.

Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Dutch Colorectal Cancer Group, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345(9):638–46.CrossRef

30.

Kulu Y, Tarantino I, Billeter AT, Diener MK, Schmidt T, Büchler MW, et al. Comparative outcomes of neoadjuvant treatment prior to total mesorectal excision and total mesorectal excision alone in selected stage II/III low and mid rectal cancer. Ann Surg Oncol. 2016;23(1):106–13.CrossRef

31.

Lacopetta B. Are there two sides to colorectal cancer? Int J Cancer. 2002;101(5):403–8.CrossRef

32.

Meguid RA, Slidell MB, Wolfgang CL, Chang DC, Ahuja N. Is there a difference in survival between right-versus left-sided colon cancers? Ann Surg Oncol. 2008;15(9):2388–94.CrossRef

Title: Clinical characteristics and prognosis of different primary tumor location in colorectal cancer: a population-based cohort study
Authors: C. Zheng
F. Jiang
H. Lin
S. Li
Publication date: 01-11-2019
Publisher: Springer International Publishing
Keywords: Colorectal Cancer
Colorectal Cancer
Published in: Clinical and Translational Oncology / Issue 11/2019
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-019-02083-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2019

Role of multi-modality functional imaging in differentiation between benign and malignant thyroid 18F-fluorodeoxyglucose incidentaloma

Effectiveness of fentanyl pectin nasal citrate in controlling episodes of breakthrough cancer pain triggered by routine radiotherapy procedures

Predictive factors for central lymph node and lateral cervical lymph node metastases in papillary thyroid carcinoma

Relation between sarcopenia and dose-limiting toxicity in patients with metastatic colorectal cancer who received regorafenib

Correction to: BRG1 regulation by miR-155 in human leukemia and lymphoma cell lines

Skin and lung toxicity in synchronous bilateral breast cancer treated with volumetric-modulated arc radiotherapy: a mono-institutional experience

Keynote webinar | Spotlight on antibody–drug conjugates in cancer